Official UK procurement notice
Contract for the supply of live attenuated intranasal influenza vaccine
Authority: Department of Health & Social Care (Central government)
What is being bought
Published requirement descriptionProvision for a contract for the supply of live attenuated intranasal influenza vaccine
CPV: Influenza vaccines
The lotProcurement structure
single lot · no lot value publishedLot #1The provision of additional doses of live attenuated intranasal influenza vaccine, to…Awarded
The provision of additional doses of live attenuated intranasal influenza vaccine, to be used to support the annual seasonal influenza vaccination programme in the UK. The additional volume requirement is 37,160 doses of vaccine.
Procedure terms & legal framework
From the official record · publisher note attached- Procedure method
- Award procedure without prior publication of a call for competition
- Legal basis
- CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)
- Procurement category
- Goods
- Notice status
- Awarded without competition
- Procurement threshold
- Unspecified in notice
- Regulatory regime
- Standard
- Commercial structure
- Stand-alone contract (no framework)
- Competition type
- Direct award (no call for competition)
- GPA / WTO covered
- Yes (GPA)
- Recurring procurement
- Unspecified in notice
- First published
- 23 Apr 2021, 10:58 BST
- Last source update
- 11 Oct 2021, 14:33 BST
- Authority reference
CM/PHV/14/5433- FTS notice number
2021/S 000-025357- Classification (CPV)
- Delivery area
- Official registry OCID
ocds-h6vhtk-02a974Find a Tender
- Why no open competition
The works, supplies or services can be provided only by a particular economic operator due to absence of competition for technical reasons
- Published justification
There is only one supplier with an exclusive global licence to manufacture and distribute this vaccine which is licensed and approved for use in the UK and due to the functions of the vaccine, there is no reasonable alternative or substitute, therefore using the negotiated procedure without prior publication is justified under Regulation 32(2)(b)(ii) and (iii) of the Public Contracts Regulations 2015.
Publisher note: Value — this information is considered by the supplier to be commercially sensitive information. The authority is not publishing the value so as not to prejudice the legitimate commercial interest of the supplier.
How it was run
Official notice- Submission deadline
- —
Timeline
1 Aug 2018 → 11 Oct 2021 · 2 dates- Contract starts1 Aug 2018, 00:00 BST
- Notice published11 Oct 2021, 14:33 BST
Notice history
3 releases on Find a TenderPublished amendments (1 · 0 deadline changes)
| When | What | Before | After | Shift |
|---|---|---|---|---|
| — | DateContract conclusion date · V.2.1.1 | 20 Mar 2021 | 21 Mar 2021 | +1 d |
| — | TextAddress of the Contractor · V.2.3.1 | AstraZeneca 1 Francis Crick Avenue, Cambridge, United Kingdom, LCB2 0AA Registration number: 3674842 | AstraZeneca UK Limited 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA Registration number: 03674842 | |
| — | TextExplanation · IV.1.1.1 | There is only one supplier with an exclusive global licence to manufacture and distribute this vaccine which is licensed and approved for use in the UK and due to the functions of the vaccine, there is no reasonable alternative or substitute, therefore using the negotiated procedure without prior publication is justified under Regulation 32(2)(b)(ii) and (iii) of the Public Contracts Regulations 2… | DHSC is procuring these vaccines on the recommendation of the JCVI that this type of vaccine should be offered . There is only one supplier of this type of vaccine with the applicable Marketing Authorisation in the UK and, due to the functions of the vaccine, there is no reasonable alternative or substitute currently licenced for use in the UK. Competition is therefore absent for technical reasons… | |
| — | TextReference number · II.1.1.2 | CM/PHV/14/5433_1 | CM/PHV/14/5433 |
1 amendment published without a description.
Commercial outcome & contract awards
Published awards, contracts and bid statistics, not a forecast| Awarded to | Value | Date | Status |
|---|---|---|---|
| ASTRAZENECA UK LIMITED | £1 †same award published again · counted once | — | Awarded |
| ASTRAZENECA UK LIMITED | £1 † | — | Awarded |
Contracts
Contract 008707-2021-1 · ASTRAZENECA UK LIMITED
- Signed
- 20 Mar 2021
- Value
- £1
- Period
- … – 31 Jul 2022
- Status
- active
Contract 025357-2021-CM/PHV/14/5433-1 · ASTRAZENECA UK LIMITED
- Signed
- 9 Feb 2018
- Value
- £1
- Period
- 1 Aug 2018 – 31 Jul 2022
- Status
- active
- Change The provision of additional doses of live attenuated intranasal influenza vaccine, to be used to support the annual seasonal influenza vaccination programme in the UK. The additional volume requirement is 37,160 doses of vaccine., Need for additional works, services or supplies by the original contractor/concessionaire: The additional doses of LAIV are necessary for the Government’s children’s flu programme; AstraZeneca have exclusive rights to manufacture and supply a LAIV product (Fluenz Tetra) and are the only supplier in the UK of a LAIV product with marketing authorisation which means DHSC cannot engage another supplier to provide the additional doses without significant inconvenience
Bid statistics published by the authority
| Bids | SME | VCSE | Valid bid range |
|---|---|---|---|
| 1bids | — | — | — |
Contracting authority & participating public bodies
Dispute resolution & review bodies
- The High CourtReview body
Bidders & participating suppliers
2 commercial parties on the notice- AstraZenecaAwarded supplier
- AstraZenecaAwarded supplier
Official documents & specifications
Official links; attachments are not copiedNo document links were published on the notice.